Low Rates of C. difficile Associated Diarrhea in Patients Receiving IVAB in the Outpatient Setting

BOSTON, MA (October 21, 2011) – Patients receiving intravenous antibiotics in seven Infectious Disease Physician Office Infusion Centers (POICs) experienced a low rate of Clostridium difficile associated diarrhea (2.5 per 10,000 patient days). Of the 934 patients treated with a causative intravenous antibiotic in the POICs, only 8 had a confirmed C. difficile infection (CDI). The POIC setting allows for quick diagnosis and treatment initiation (average 2.7 days from symptom onset), contributing to an 88% success rate for those patients treated for a confirmed CDI.

This study was presented at the 49th Annual Meeting of the Infectious Diseases Society of America (IDSA). For a printed copy of this research poster study, please call 1.866.654.2451 or email [email protected].

Healix is the national leader in the delivery of parenteral services to medical facilities. The privately-held company is based in Sugar Land, Texas, and offers customizable, turn-key solutions to help healthcare providers offer streamlined infusion therapy and related care.

The 49th Annual Meeting of the Infectious Diseases Society of America (IDSA) brought together physicians, scientists, and other health care professionals involved in research, patient care, public health, disease prevention, and education in the field of infectious diseases. The meeting showcased the latest news in the field of infectious diseases with emphasis on contemporary trends, including emerging infections, new diagnostic and therapeutic advances. IDSA 2011 took place October 20-23 at the Boston Exhibition and Convention Center in Boston, Massachusetts. For more information, visit www.idsa2011.org.

Lucinda J. Van Anglen, PharmD
Healix, Inc.
t: 281.295.4000
e: [email protected]

View All

Phase II and Phase III Studies

Healix regularly and actively supports Phase II and Phase III clinical trials in each of our specialty areas, including active studies in therapies for COVID-19, Multiple Sclerosis and Intestinal Bowel Disease.

For information on partnering with Healix on a study, please contact us.